RRML - Hypoxia-inducible factor HIF-1α: pharmacogenetic perspective for bevacizumab therapy individualization

Main page
News
RJLabM Credits
Archive
- Current issue
- Ahead of print
- List of published issues
- 2024
  - Nr.1/2024
- 2023
  - Nr.4/2023
  - Nr.3/2023
  - Nr.2/2023
  - Nr.1/2023
  - Supplement 1/2023
- 2022
  - Nr.4/2022
  - Nr.3/2022
  - Nr.2/2022
  - Nr.1/2022
  - Supplement 1/2022
- 2021
  - Nr.4/2021
  - Nr.3/2021
  - Nr.2/2021
  - Nr.1/2021
- 2020
  - Nr.4/2020
  - Nr.3/2020
  - Nr.2/2020
  - Nr.1/2020
  - Supplement 1/2020
- 2019
  - Nr.4/2019
  - Nr.3/2019
  - Nr.2/2019
  - Nr.1/2019
  - Supplement 1/2019
- 2018
  - Nr.4/2018
  - Nr.3/2018
  - Nr.2/2018
  - Nr.1/2018
  - Supplement 1/2018
  - Supplement 2/2018
  - Supplement 3/2018
- 2017
  - Nr.4/2017
  - Nr.3/2017
  - Nr.2/2017
  - Nr.1/2017
  - Supplement 1/2017
- 2016
  - Nr.4/2016
  - Nr.3/2016
  - Nr.2/2016
  - Nr.1/2016
  - Supplement 1/2016
- 2015
  - Nr.4/2015
  - Nr.3/2015
  - Nr.2/2015
  - Nr.1/2015
  - Supplement 1/2015
- 2014
  - Nr.4/2014
  - Nr.3/2014
  - Nr.2/2014
  - Nr.1/2014
  - Supplement 1/2014
- 2013
  - Nr.4/2013
  - Nr.3/2013
  - Nr.2/2013
  - Nr.1/2013
  - Supplement 1/2013
- 2012
  - Nr.4/2012
  - Nr.3/2012
  - Nr.2/2012
  - Nr.1/2012
  - Supplement 1/2012
- 2011
  - Nr.4/2011
  - Nr.3/2011
  - Nr.2/2011
  - Nr.1/2011
  - Supplement 1/2011
- 2010
  - Nr.4/2010
  - Nr.3/2010
  - Nr.2/2010
  - Nr.1/2010
  - Supplement 1/2010
- 2009
  - Nr.4/2009
  - Nr.3/2009
  - Nr.2/2009
  - Nr.1/2009
  - Supplement 1/2009
- 2008
  - Nr.4/2008
  - Nr.3/2008
  - Nr.2/2008
  - Nr.1/2008
  - Supplement 1/2008
- 2007
  - Nr.4/2007
  - Nr.3/2007
  - Nr.2/2007
  - Nr.1/2007
- 2006
  - Nr.4/2006
  - Nr.3/2006
  - Nr.2/2006
  - Nr.1/2006
- 2005
  - Nr.1/2005
Instructions for authors
Online applications
- Send an article
- Online payments
Editorial
About us
Links

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12

Top 10 downloaded articles - April 2024 -

A comprehensive review of Prof...	25
Recomandarea comună EFLM-COLA...	15
Anti-thyroid peroxidase (TPO) ...	11
Monocyte to high-density lipop...	10
Understanding the key differen...	9
Understanding the pathogenesis...	7
Predictive value of expression...	7
Romanian Review of Laboratory ...	6
Function of the S1P pathway in...	6
The importance of tumor marker...	5

Concept, Design & Programming
Dr. Adrian Man

Nr. 16(3)/2009

Hypoxia-inducible factor HIF-1α: pharmacogenetic perspective for bevacizumab therapy individualization

Roxana-Georgiana Tauser, Eloae Florin Zugun, Daniela Jitaru, Eugen Carasevici

Abstract:

Pharmacogenetics of innovative angiogenic-targeted monoclonal antibody therapy, yet in its infancy, will be crucial in treatment individualization according to the genetic profile of each patient and molecular features of tumors. Bevacizumab (Avastin) specifically targets the key promotor of angiogenesis - vascular endothelial growth factor (VEGF), whose transcription is critically regulated by hypoxia-inducible factor HIF-1α. The present paper points out the clinical relevance of HIF-1α common genetic polymorphisms to the inter-individual variability in response to anti-VEGF-targeted monoclonal antibody therapeutic regimens, with special reference to colorectal cancer.

Keywords: pharmacogenetics,bevacizumab,hypoxia inducible factor,cancer

Download full text PDF
(253 KB)

Tauser RG, Zugun EF, Jitaru D, Carasevici E. Hypoxia-inducible factor HIF-1α: pharmacogenetic perspective for bevacizumab therapy individualization. Rev Romana Med Lab. 2009;16(3):7-12